stockrowExelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
Follow EXEL
Alert me
Exelixis, Inc. (EXEL) Gross margin
Exelixis, Inc.'s gross margin over the twelve months to 30 September 2026 was 96.3%, down 0.1 percentage points from fiscal 2025 (96.4%). Over the past ten years it has ranged from 89.5% (fiscal 2015) to 96.9% (fiscal 2018); the current reading is higher than 45% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 96.4% | (0.10) |
| FY2024 | 96.5% | 0.45 |
| FY2023 | 96.0% | (0.37) |
| FY2022 | 96.4% | 0.09 |
| FY2021 | 96.3% | (0.01) |
| FY2020 | 96.3% | (0.25) |
| FY2019 | 96.6% | (0.33) |
| FY2018 | 96.9% | 0.24 |
| FY2017 | 96.7% | 0.09 |
| FY2016 | 96.6% | 7.06 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 96.0% | (0.69) |
| Jun 2026 | 96.7% | (0.02) |
| Mar 2026 | 96.7% | 1.15 |
| Dec 2025 | 95.6% | (1.31) |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| SMMT Summit Therapeutics PLC compare | 100.0% |
| EXEL Exelixis, Inc. | 96.3% |
| BBIO BridgeBio Pharma, Inc. compare | 94.3% |
| ASND Ascendis Pharma A/S compare | 91.3% |
| JAZZ Jazz Pharmaceuticals PLC compare | 89.1% |
| INSM Insmed, Inc. compare | 84.4% |
| HALO Halozyme Therapeutics, Inc. compare | 82.3% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 77.3% |
| BNTX BioNTech SE Sponsored ADR compare | 74.6% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on EXEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement